ZTSZoetis Inc.

$54B

Q1 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$2.0B+0.7% YoY

Gross Profit

$1.4B68.8% margin

Operating Income

$728M36.4% margin

Net Income

$552M27.6% margin

EPS (Diluted)

$1.19

QoQ Revenue Growth

-2.0%

Cash Flow

Operating Cash Flow

$549M

Free Cash Flow

$326M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$13.8B

Total Liabilities

$9.3B

Stockholders' Equity

$4.5B

Cash & Equivalents

$2.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.0B	$2.0B	+0.7%
Gross Profit	$1.4B	$1.4B	-0.1%
Operating Income	$728M	$789M	-7.7%
Net Income	$552M	$595M	-7.2%

Revenue Segments

Dogs and Cats

$1.2B59%

Cattle

$399M20%

Swine

$142M7%

Poultry

$139M7%

Horses

$72M4%

Fish

$49M3%

Geographic Segments

United States Segment

$1.0B51%

International Segment

$978M49%

ZTS Q1 2023 Earnings — Zoetis Inc. Revenue & Financial Results | Market Cap Arena